The subjects involving the novel coronavirus and the covid vaccines continue to flood social media. Check out the latest reports about Moderna and Pfizer.
According to the latest reports coming from CNBC, the two companies expect $51 billion in combined vaccine sales in the coming year.
This is happening even as the omicron wave dramatically subsides in many parts of the world and both of the pharmaceutical giants believe the pandemic is shifting into an endemic phase where the virus will be less disruptive to society.
“Pfizer expects $32 billion in Covid vaccine sales for 2022, while Moderna is forecasting at least $19 billion in sales, the companies said in their fourth-quarter earnings statements released last month.”
These are minimum sales, and it’s also important to note the fact that they are reflecting contracts that have already been signed by nations across the world anticipating their need for the year.
CNBC noted that they could be far higher, depending on the trajectory of the virus.
“Pfizer just raised its 2022 Covid vaccine sales guidance by $1 billion from its previous forecast given to investors in the third quarter while Moderna upped its guidance by $2 billion.”
The CNBC article is addressing what is next for the two companies and we suggest that you check out the notes in order to learn more details.
Antibody therapy for fighting covid
The other day, we revealed that the Chinese experts have just said they have developed an antibody therapy to treat and prevent severe Covid-19, which has been shown to be effective in animals.
They said the treatment does the following:
“retains neutralising ability to most Sars-CoV-2 variants of concern, with more potent neutralising activity against the Delta variant”.
According to the latest important reports, the team, from institutes including the Chinese Academy of Sciences, Capital Medical University, and China’s Centre for Disease Control, published their findings in the peer-reviewed journal Nature Immunology on Tuesday.
Stay tuned for more news.